Our research is focused on the transcriptional pathways that underlie metabolic diseases like obesity and Type 2 diabetes. In particular, we have a longstanding interest in using genomic and epigenomic approaches to identify novel transcription factors and pathways that regulate processes such as adipogenesis, lipid handling, insulin resistance, and metabolic memory. Our ultimate goal is to define novel targets that can be manipulated to improve outcomes in metabolic disease.
- Suraj Patel has received the American Gastroenterological Association Research Scholar award
This is a research career development award that provides funding for 3 years. Suraj has previously found that Interferon Regulatory Factor 3 (IRF3) plays an essential role in obesity-induced non-alcoholic fatty liver disease (NAFLD). Mice deficient in IRF3 (IRF3KO) are protected against steatosis and hepatic insulin resistance induced by high fat diet. Genome-wide transcriptional profiling of IRF3KO and wild-type mice on HFD revealed two candidate IRF3 target genes, Isg15 and Srebf1, mediating IRF3-induced hepatic steatosis and insulin resistance. The aims of this project are to identify the hepatic cell type(s) responsible for IRF3-mediated steatosis and IR in NAFLD, and define the role of ISG15 and SREBP1 in promoting IRF3-induced metabolic dysfunction.
Congratulations on the grant Suraj!
- New paper in Molecular Metabolism